Liquid biopsy biosensing for cancer therapies using LNA technology

Dr. Kevin M. Koo is dedicated to improving the biosensing performance of circulating nucleic acid detection for liquid biopsies. A major issue with liquid biopsy biosensing is the need to pick up a small cancer mutation signal from a lot of background noise of normal sequences. The objective is to suppress this background noise effectively and leave the mutated targets for detection using highly sensitive readout nanotechnologies.

Using locked nucleic acid (LNA)-modified bases to control molecular sequence hybridization of multiple targets instead of thermal cycling, Kevin and his coworkers achieved ultraselective multiplexed detection of cancer gene fusion nucleic acid variants. They recently introduced a novel nanosensor using "locker probe" enrichment and magneto-bioelectrocatalytic cycling to detect multiple gene fusion mutant variants in real patient liquid biopsies. In this video, he describes how the approach overcomes the challenge of detecting trace copies of the biotarget in the high non-target background of highly similar native and variant NA sequences.

🔥 Subscribe to our channel now

..............................................................
Follow us now
..............................................................